All In Biotech

Drug Trial Radar · NCT07926893

Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome

A Phase 1 Study of Cosibelimab (CK-301; UNLOXCYT) in Combination With Lenalidomide in Patients With Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

14

Planned (sponsor's estimate)

Start

May 16, 2027

Primary completion

May 16, 2028

Study completion May 16, 2028

Sponsor

Lead sponsor
City of Hope Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety, side effects and best dose of lenalidomide in combination with cosibelimab for the treatment of patients with mycosis fungoides or Sézary syndrome that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory).Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Immunotherapy with monoclonal antibodies, such as cosibelimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide in combination with cosibelimab may be safe and tolerable in treating patients with relapsed or refractory mycosis fungoides or Sézary syndrome.

Conditions

  • Recurrent Mycosis Fungoides
  • Recurrent Sezary Syndrome
  • Recurrent Transformed Mycosis Fungoides
  • Refractory Mycosis Fungoides
  • Refractory Sezary Syndrome
  • Refractory Transformed Mycosis Fungoides
  • Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
  • Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8
  • Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8
  • Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT scan

  • CosibelimabDrug

    Given IV

  • LenalidomideDrug

    Given PO

  • Positron Emission TomographyProcedure

    Undergo PET scan

  • Questionnaire AdministrationOther

    Ancillary studies

  • Skin BiopsyProcedure

    Undergo skin biopsy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLT)Time frame: From baseline, up to completion of cycle 3 (cycle length = 21 days)
  2. Incidence of adverse eventsTime frame: Up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.